Assessment of nuclear grade-based recurrence risk classification in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative, node-positive high-risk early breast cancer.

Although the 5-year IDFS rate for group 2 was not significantly different from those for groups 1 and 4, there was a slightly significant trend (84.2% vs. 88.2%, P = 0.2728; 81.6% vs. 88.2%, P = 0.0953, respectively) (Online Resource Fig. 1a).

also in 1,762 other papers